Patient-Derived Dermal Fibroblasts for Early Parkinson's Biomarker Detection
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease are inadequate due to the complex etiology and late-stage diagnosis, leading to a need for reliable biomarkers that can identify early stages and track progression effectively.
Innovation Solution
A method utilizing patient-derived primary dermal fibroblasts to generate a diagnostic biomarker profile by analyzing growth dynamics, morphology, oxidative stress, mitochondrial function, and autophagy, with exposure to external agents like UV irradiation to induce stress and reveal PD-related mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If clinical diagnosis methods are used for Parkinson's disease, then diagnosis can be performed, but diagnosis occurs at late stage when 60-70% of neurons have already degenerated
Solution Approach 1:
The patent applies preliminary action by using patient-derived fibroblasts to detect PD-related molecular changes (alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress) before clinical symptoms appear. This allows early diagnosis by identifying pathological processes in peripheral cells that reflect neuronal damage, enabling intervention before 60-70% neuron degeneration occurs.
2Adaptability or versatility
If genetic PD patient fibroblasts are analyzed, then specific molecular processes can be studied, but sporadic PD cases (90% of cases) cannot be effectively investigated
Solution Approach 1:
The patent applies universality by developing a fibroblast-based diagnostic platform that works for both genetic and sporadic PD cases. The method detects universal PD pathogenic mechanisms (alpha-synuclein pathology, mitochondrial dysfunction, oxidative stress) that occur in all PD patients regardless of genetic background, making it applicable to 90% of sporadic cases while maintaining reliability.
3Ease of operation
If non-neuronal cells are used as disease models, then accessible patient-specific samples can be obtained, but neuronal-specific PD mechanisms may not be captured
Solution Approach 1:
The patent applies the intermediary principle by using fibroblasts as a proxy that reflects neuronal pathology. Fibroblasts serve as an accessible intermediary tissue that exhibits PD-related molecular changes (alpha-synuclein aggregation, mitochondrial dysfunction) mirroring neuronal damage, allowing indirect but reliable detection of neuronal disease mechanisms through peripheral blood or skin samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of distinct alterations in PD fibroblasts, enabling early diagnosis and monitoring of disease progression, providing a robust platform for developing peripheral biomarkers that reflect PD molecular changes.
Implementation Method 1
exposing said biological sample in the medium to an external agent for a period of time to induce stress in said biological sample
Data Source
AI summary
Primary skin fibroblasts obtained from individuals diagnosed with late-onset sporadic Parkinson's disease (PD), were compared to healthy age-matched controls. Fibroblasts from PD subjects had higher growth rates, and appeared distinctly different in terms of morphology and spatial organization in culture, compared to control cells. The PD fibroblasts also exhibited significantly compromised mitochondrial structure and function when assessed via morphological and oxidative phosphorylation assays. Additionally, an increase in baseline macroautophagy levels was seen in cells from PD subjects. Exposure of the skin fibroblasts to physiologically relevant stress, specifically ultraviolet irradiation (UVA), further exaggerated the autophagic dysfunction in the PD cells. Moreover, the PD fibroblasts accumulated higher levels of reactive oxygen species (ROS) coupled with lower cell viability upon UVA treatment. These results highlight primary skin fibroblasts as a patient-relevant model that captures fundamental PD molecular mechanisms, and enable their utility as diagnostic and prognostic biomarkers for PD.